Mr. Andre Godin reports

INTELGENX TO REPORT FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS ON MARCH 30, 2023 - CONFERENCE CALL TO FOLLOW

IntelGenx Technologies Corp. will release its fourth quarter and full-year 2022 financial results after market close on Thursday, March 30, 2023.

An accompanying conference call will be hosted by Dr. Horst G. Zerbe, chief executive officer, and Andre Godin, president and chief financial officer, to discuss the results and provide a business update. Details of the conference call and webcast are below:

Fourth quarter and full-year 2022 results conference call details:

Date: Thursday, March 30, 2023

Time: 4:30 p.m. ET

Live call: 1- 888-506-0062 (Canada and the United States) or 1-973-528-0011 (international)

Access code: 884881

The call will also be broadcast live and archived on the company's website under "webcasts" in the investors section.

About IntelGenx Technologies Corp.

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx's superior film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allow for next-generation pharmaceutical products that address unmet medical needs. IntelGenx's innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

We seek Safe Harbor.